Effect over coagulation and fibrinolysis parameters of a prolonged release 24 + 4 daily use regime contraceptive formulation containing 2 mg dienogest/0.02 mg ethinylestradiol
Background A prolonged release combined oral contraceptive (COC) pill, containing 2 mg dienogest (DNG)/0.02 mg ethinylestradiol (EE) in a 24 + 4 daily dosing regimen has recently been approved in Europe.Objective To determine if this COC impacts coagulation and fibrinolytic factors in comparison to...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Gynecological Endocrinology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/09513590.2025.2458708 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|